Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab [PDF]
Therapeutic Advances in Gastroenterology, 2019 Background: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate ...
Fernando Magro +19 more
doaj +2 more sources
The role of soluble suppression of tumorigenicity 2 in pulmonary hypertension: a systematic review and meta-analysis. [PDF]
Am Heart J PlusCao L, Teng W, Sang L, Xu X.
europepmc +2 more sources
Lack of prognostic significance for major adverse cardiac events of soluble suppression of tumorigenicity 2 levels in patients with ST-segment elevation myocardial infarction. [PDF]
Cardiol J, 2021 Background: Elevation of soluble suppression of tumorigenicity 2 (sST2) is associated with cardiac fibrosis and hypertrophy. Under investigation herein, was whether sST2 level is associated with major adverse cardiac events (MACE) and left ventricular ...
Kim M +8 more
europepmc +2 more sources
A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. [PDF]
J Geriatr Cardiol, 2017 Luk KS +13 more
europepmc +3 more sources
Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure
Frontiers in Cardiovascular Medicine, 2022 BackgroundThis study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).MethodsThis was a prospective cohort ...
Zeyu Wang +9 more
doaj +1 more source
Performance Evaluation of AFIAS ST2 and Ichroma ST2 Assays in Comparison with Presage ST2 Assay
Reviews in Cardiovascular Medicine, 2023 Background: Elevated soluble suppression of tumorigenicity 2 (sST2) levels may predict mortality in heart failure (HF) patients. The AFIAS ST2 assay (AFIAS ST2, Boditech Med Inc., Chuncheon, Korea) and ichroma ST2 assay (ichroma ST2, Boditech Med Inc ...
Hanah Kim +6 more
doaj +1 more source
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure
JACC: Heart Failure, 2017 The purpose of this study was to perform the first meta-analysis of currently available data.Soluble suppression of tumorigenesis 2 (sST2) plasma concentration is elevated in chronic heart failure (CHF) and helps to predict prognosis in this setting, although the evidence is limited.Three databases (Medline, Cochrane Library, and Scopus) were searched.
Alberto Aimo +9 more
openaire +3 more sources
Indian Journal of Dental Research, 2022 Context: Interleukin-33 and its receptor soluble suppression of tumorigenicity 2 (sST2) play an important role in inflammation and its role in periodontal disease is yet unclear.
Himadri Singh +2 more
doaj +1 more source
International Journal of Clinical Practice, 2021 Gestational diabetes mellitus (GDM) is the most common pregnancy-related disease that increases the risk of metabolic disorders for the pregnancies and their offspring. GDM could be effectively prevented by early diagnosis and timely treatment.120 patients with GDM and 108 gestational week-matched pregnancies with normal glucose tolerance (NGT) were ...
Wei, Fan +6 more
openaire +2 more sources
Serum ST2 as an early predictor of heart failure in pediatric congenital heart disease. [PDF]
Zagazig University Medical JournalBackground: Heart failure (HF) is a serious consequence that can have varying effects on newborns and children with congenital heart disease (CHD). The soluble isoform of tumor suppression-2 (sST2) has become an interesting promising biomarker of heart ...
Marwa Mohammed Rashad +3 more
doaj +1 more source